Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates | Business Wire

JERSEY CITY, N.J.–( BUSINESS WIRE )–Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai Henlius Biotech, Inc. (2696.HK), whereby Organon will license commercialization rights for biosimilar candidates referencing Perjeta ® (pertuzumab, HLX11) and Prolia ® /Xgeva ® (denosumab, HLX14).

Read the source article at businesswire.com
2022-06-13 01:00:00